Roche's strong sales growth in Q1 2026 highlights the effectiveness of its innovative medicines, particularly in oncology and multiple sclerosis. The positive phase III results for key assets position Roche favorably against competitors, suggesting potential for increased market share and revenue. Regulatory context from MHRA (Clinical trials for medicines: modifying a clinical trial approval) supports the near-term read. Assessment grounded in 25 ranked evidence items (0 high-relevance).